MedTrace Logo

A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers

NCT02005211 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2016-11-04

Study results available
· View outcomes & findings →

Summary

This study consists of two parts, ie, single dose part with young healthy subjects (Part 1) and single and multiple dose part with elderly healthy subjects (Part 2), to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD3293 following single and multiple ascending dose administration to healthy subjects.

Conditions

  • Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers

Interventions

DRUG

AZD3293

Oral solution

DRUG

Placebo

Oral solution

Sponsors & Collaborators

Principal Investigators

  • Robert C Alexander, MD · AstraZeneca

  • Kei Sakamoto, MD, PhD · Sugioka Memorial Hospital, Medical Co. LTA

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02005211 on ClinicalTrials.gov